インディアナ州における子宮内膜がんの臨床試験
インディアナ州内の拠点で、子宮内膜がんに関する19件の研究が参加者を募集しています。
インディアナ州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UChicago Medicine Northwest Indiana, Crown Point
- Woodland Cancer Care Center, Michigan City
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- UChicago Medicine Northwest Indiana, Crown Point
- Goshen Center for Cancer Care, Goshen
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Northwest Cancer Center - Crown Point, Crown Point
- Northwest Oncology LLC, Dyer
- Northwest Cancer Center - Hobart, Hobart
- 他6件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/28更新 · NCT05112601Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Community Health Network, Indianapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Parkview Research Center ( Site 6008), Fort Wayne
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
被験者募集中第1相
15歳以上 · 全性別 · 2026/08/25更新 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Riley Hospital for Children, Indianapolis
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
- Indiana University, Indianapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT07306559A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Ascension St. Vicent Hospital, Inc., Indianapolis
被験者募集中第2相
18歳以上 · 女性 · 2026/08/21更新 · NCT05548296A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Community Health Network, Indianapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Fort Wayne
- Research Site, Indianapolis
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- Parkview Research Center, Fort Wayne
被験者募集中第3相
18歳以上 · 女性 · 2026/07/28更新 · NCT07022483Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of LY4175408 in Participants With Advanced Cancer
- Community Health Network, Indianapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Community Health Network, Indianapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Community Health Network, Inc., Indianapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/02/13更新 · NCT05669430Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Parkview Research Center, Fort Wayne
- Indiana University, Indianapolis
被験者募集中第2/3相
18歳以上 · 女性 · 2024/05/02更新 · NCT05797831ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。